An integrative genomics approach for associating GWAS information with triple-negative breast cancer

Cancer Informatics

Volumn 12, Issue , 2013, Pages 1-20

  Hicks, Chindo ^a,b   Kumar, Ranjit ^a   Pannuti, Antonio ^a   Backus, Kandis ^a   Brown, Alexandra ^b   Monico, Jesus ^b   Miele, Lucio ^a  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Triple negative breast cancer GWAS gene expression

Indexed keywords

BIOLOGICAL MARKER; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P53;

APOPTOSIS; ARTICLE; BASE MISPAIRING; BREAST CARCINOGENESIS; CANCER CLASSIFICATION; CANCER PATIENT; CANCER RISK; DNA REPAIR; EXCISION REPAIR; GENE EXPRESSION; GENE IDENTIFICATION; GENE MAPPING; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOMICS; HUMAN; MOLECULAR EPIDEMIOLOGY; PATIENT CODING; SINGLE NUCLEOTIDE POLYMORPHISM; TRIPLE NEGATIVE BREAST CANCER;

EID: 84873448622     PISSN: None     EISSN: 11769351     Source Type: Journal    
DOI: 10.4137/CIN.S10413     Document Type: Article

References (62)

1. Stratton MS, Rahman N. The emerging landscape of breast cancer susceptibility. Nat Genet. 2008;40(1):17-22.
2. Hicks C, Asfour R, Pannuti A, Miele L. An integrative genomics approach to biomarker discovery in breast cancer. Cancer Inform. 2011;10:185-204.
3. Zhang B, Beeghly-Fadiel A, Long J, Zheng W. Genetic variants associated with breast-cancer risk: Comprehensive research synopsis, meta-analysis, and epidemiology evidence. Lancet Oncol. 2011;12:477-88.
4. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res. 2007;13: 4429-434.
5. Carey L, Winer E, Viale G, Cameron D, Gianni L. Triple-negative breast cancer: disease entity or title of convenience. Nat Rev Clin Oncol. Dec 2010; 7(12):683-692.
6. Bosch A, Eroles P, Zaragoza R, Vina JR, Lluch A. Triple-negative breast cancer: Molecular features, pathogenesis, treatment and current lines of research. Cancer Treat Rev. 2010;36:206-215.
7. Hudis CA, Gianni L. Triple-negative breast cancer: An unmet medical need. Onclogist. 2011;16(Suppl 1):1-11.
8. Perou CM. Molecular stratifcation of triple-negative breast cancers. Oncologist. 2010;15(Suppl 5):39-48.
9. Schneider BP, Winer EP, Foulkes WD, et al. Triple negative breast cancer: risk factors to potential targets. Clin Cancer Res. 2008;14:8010-8018.
10. Curigliano G, Goldhirsch A. The triple-negative subtype: New ideas for the poorest prognosis breast cancer. J Natl Cancer Inst Monogr. 2011;43: 108-110.
11. Yang W-T, Dryden M, Broglio K, et al. Mammographic features of triple-negative primary breast cancers in young premenopausal women. Breast Cancer Res Treat. Oct 2008;111(3):405-410. Epub Nov 17, 2007.
12. Dawood S. Triple-negative breast cancer. Epidemiology and management options. Drugs. 2010;70(17):2247-2258.
13. Turner N, Lambros MB, Horlings HM, et al. Integrative molecular profiling of triple-negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene. 2010;29(14):2013-2023.
14. Kreike B, van Kouwenhove M, Horlings H, et al. Gene expression profiling and histopathology characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res. 2007;9:R65.
15. Lehmann BD, Bauer JA, Chen X, et al. Identifcation of triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2012. doi:10.1172/JCI45014.
16. Stevens KN, Vachon CM, Lee AM, et al. Common breast cancer susceptibility loci are associated with triple-negative breast cancer. Cancer Res. 2011;71(19):6240-6249.
17. Stevens KN, Fredericksen Z, Vachon CM, et al. 19p13.1 Is a triple- negative-specific breast cancer susceptibility locus. Cancer Res. 2012;72(7): 1975-1803.
18. Ioannidis JP, Boffetta P, Little J, et al. Assessment of cumulative evidence on genetic associations: Interim guidelines. Intl J Epidemiol. 2008;37: 120-132.
19. Khoury MJ, Bertram I, Boffetta P, et al. Genome-wide association studies, field synopses, and the development of the knowledge base on genetic variation in human diseases. Am J Epidemiol. 2009;170:269-279.
20. Sagoo GS, Little J, Higgins JP. Systematic reviews of genetic association studies. PLoS Med. 2009;6:e28.
21. Moher D, Liberati A, Tetzlaff J, Altman DG; for the PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264-269.
22. Liberati A, Altman DG, Tetzlaff J, Mulrow C, et al. The PRISMA statement for reporting systematic reviews and meta-analyses studies that evaluate health care interventions: Explanation and elaboration. PLoS Med. 2009; 6(7):e1000100.
23. Holmans P, Green EK, Pahwa JS, et al. Gene ontology analysis of GWA study data sets provides insights into biology of bipolar disorder. American J Hum Genet. 2009;85:13-24.
24. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Eng J Med. 2010;363:1938-1948.
25. Sabatier R, Finetti P, Cervera N, et al. A gene expression signature identifies two prognostic subgroups of basal breast cancer. Breast Cancer Res Treat. 2011;126:407-420.
26. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucl Acids Res. 2002;30(1):207-210.
27. Richardson AL, Wang ZC, De Nicolo A, et al. X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell. 2006;9:121-132.
28. Chen D, Nasir A, Culhane A, et al. Proliferative genes dominate malignancy-risk gene signature in historically-normal breast cancer: Breast Cancer Res Treat. 2010;119(2):335-346.
29. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Nat Acad Sci U S A. 1998;95:14863-14868.
30. Reich M, Liefield T, Gould J, Lerner J, Tamayo P. GenePattern 2.0. Nat Genet. 2006;38(5):500-501.
31. Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J Royal Stat Soc. Series B Methodology. 1995;57(1):289-300.
32. RadMacher MD, McShane LM, Simon R. A paradigm for class prediction using gene expression profles. J Comput Biol. 2002;9(3):505-511.
33. Morrissey ER, Diaz-Uriarte R. Pomello II: Finding differentially expressed genes. Nucl Acids Res. 2009;37:W581-586.
34. Ashburner M, Ball CA, Blake JA, et al. Gene ontology: tool for the unification of biology. The Gene Ontolgy Consortium. Nat Genet. 2000;25(1):25-29.
35. Ingenuity Pathways Analysis (IPA) system. Ingenuity Incorporated, California.
36. Rakha EA, Elsheikh SE, Aleskandarany MA, et al. Triple-negative breast cancer: Distinguishing between basal and nonbasal subtypes. Clin Cancer Res. 2009;15(7):2302-23010.
37. Shah SP, Roth A, Goya R, Oloumi A, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature. Apr 4, 2012; 486(7403):395-399.
38. Curtis C, Shah SP, Chin SF, et al. The genomic transcriptomic architecture of 2,000 breast tumors reveals novel subgroups. Nature. Apr 18, 2012;486(7403):346-352.
39. Stacey SN, Manolescu A, Sulem P, et al. Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet. 2008;40:703-706.
40. Figueroa JD, Garcia-Closas M, Humphries M, et al. Association of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: Findings from the Breast Cancer Association Consortium. Hum Mol Genet. 2011;20:4693-706.
41. Broekes A, Schmidt MK, Sherman ME, et al. Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: Findings from Breast Cancer Association Consortium. Hum Mol Genet. 2011;20:3289-3303.
42. Lee E, McKean-Cowdin R, Ma H, et al. Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: Results from a population-based study of young women. J Clin Oncol. 2011;29:4373-4380.
43. Alberti S, Ambrogi F, Pedriali M, et al. p53 status splits triple-negative breast cancer in subgroups with distinct predictive and prognostic potential value. Cancer Res. 2009;69(24 Suppl 3).
44. Biganzoli E, Coradini D, Ambrogi F, et al. p53 status identifies two subgroups of triple-negative breast cancers with distinct biological features. Jpn J Clin Oncol. 2011;41(2):172-179.
45. Silver DP, Richardson AL, Eklund AC. Efficacy of Neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol. 2010;28(7):1145-1153.
46. Tommiska J, Bartkova J, Heinonen M, et al. The DNA damage signaling kinase ATM is aberrantly reduced or lost in BRCA1/BRAC2-diffent and ER/PR/ERBB2-triple-negative breast cancer. Oncogene. 2008;27: 2501-2506.
47. Zhang Y, Newcomb PA, Egan KM, et al. Genetic polymorphisms in base-excision repair pathway genes and risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 2006;15(2):353-358.
48. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917-920.
49. Ma CX, Cai S, Li S, et al. Targeting Chk1 in p53-diffent triple-negative breast cancer is the therapeutically benefcial in human-in-mouse tumor models. J Clin Invest. 2012;122(4):1541-1552.
50. Chae BJ, Bae JS, Lee A, et al. p53 as a specific prognostic factor in triple-negative breast cancer. Jpn J Clin Oncol. 2009;39(4)217-224.
51. Hsieh P, Yamane K. DNA mismatch repair: Molecular mechanisms, cancer, and ageing. Mech Age Develop. 2008;129:391-407.
52. Tapper W, Hammond V, Gerty S, et al. The influence of genetic variation in 30 selected genes on the clinical characteristics of early onset breast cancer. Breast Cancer Res. 2008;10(6):R108.
53. Prat A, Parker JS, Karginova O, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010;12:R68.
54. Hicks C, Pannuti A, Miele L. Associating GWAS information with the Notch signaling pathway using transcription profiling. Cancer Inform. 2011;10:93-108.
55. Hicks C, Kumar R, Pannuti A, Miele L. Integrative analysis of response to tamoxifen treatment in ER-positive breast cancer using GWAS information and transcription profiling. Breast Cancer: Basic Clin Res. 2012:47-66.
56. Paracios R, Gazave E, Goni J, et al. Allelle-specific gene expression is widespread across the genome and biological processes. PLoS One. 2009;4(1):e4150.
57. Cheung VG, Conclin LK, Weber TM, et al. Natural variation in human gene expression assessed in lymphoblastoid cells. Nat Genet. 2003;33:422-423.
58. Buckland PR. Allele-specific gene expression differences in humans. Hum Mol Genet. 2004;13(2):R255-260.
59. Yan H, Yuan W, Velculescu VE, Vogelstein B, Kinzler KW. Allelic variation in human gene expression. Science. 2002;297:1143.
60. Reis-Filho JS, Tutt ANJ. Triple negative tumors: a critical review. Histopathology. 2008;52:108-118.
61. Stead LA, Lash TL, Sobieraj JE, et al. Triple-negative cancers are increased in black women regardless of age or body mass index. Breast Cancer Res. 2009;11:R18.
62. Huo D, Ikpatt F, Khramtsov A, et al. Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple negative breast cancer. J Clin Oncol. 2009;27(27):4515-4521.